{"id":"zidovudine-lamivudine-lopinavir-ritonavir","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Nausea"},{"rate":"15-25","effect":"Diarrhea"},{"rate":"10-20","effect":"Headache"},{"rate":"10-15","effect":"Lipodystrophy"},{"rate":"5-10","effect":"Hyperglycemia"},{"rate":"<1","effect":"Lactic acidosis"},{"rate":"5-10","effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL26318","moleculeType":"Small molecule","molecularWeight":"267.24"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Zidovudine and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that prevent the virus from converting its RNA genome into DNA. Lopinavir/ritonavir is a protease inhibitor combination where ritonavir boosts lopinavir levels; together they block the protease enzyme needed to process viral proteins. This triple-drug regimen targets multiple steps in the HIV replication cycle.","oneSentence":"This combination inhibits HIV replication by blocking reverse transcriptase (zidovudine and lamivudine) and protease (lopinavir/ritonavir) enzymes required for viral reproduction.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:16:32.793Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT02369406","phase":"PHASE2, PHASE3","title":"Early Infant HIV Treatment in Botswana","status":"ACTIVE_NOT_RECRUITING","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2015-05-04","conditions":"HIV, Pediatric AIDS","enrollment":67},{"nctId":"NCT07080138","phase":"","title":"Research on the Psychological Status of Patients With HIV-1 Infection","status":"NOT_YET_RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-01","conditions":"HIV-1-infection, Anxiety Depression","enrollment":500},{"nctId":"NCT00955968","phase":"PHASE4","title":"IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2010-01-01","conditions":"HIV Infection","enrollment":1653},{"nctId":"NCT02712801","phase":"PHASE4","title":"Antiretroviral Regime for Viral Eradication in Newborns","status":"COMPLETED","sponsor":"National Center for Women and Children's Health, China CDC","startDate":"2016-04","conditions":"HIV/AIDS and Infections","enrollment":600},{"nctId":"NCT01061151","phase":"PHASE3","title":"Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-03-01","conditions":"HIV Infections","enrollment":3747},{"nctId":"NCT00074581","phase":"PHASE3","title":"Preventing Sexual Transmission of HIV With Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-02","conditions":"HIV Infections","enrollment":3526},{"nctId":"NCT00039741","phase":"PHASE2, PHASE3","title":"Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-08","conditions":"HIV Infections","enrollment":266},{"nctId":"NCT00084149","phase":"PHASE2","title":"Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-02","conditions":"HIV Infections","enrollment":54},{"nctId":"NCT00099632","phase":"PHASE2","title":"Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-03","conditions":"HIV Infections","enrollment":484},{"nctId":"NCT00102960","phase":"PHASE3","title":"Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-07","conditions":"HIV Infections","enrollment":377},{"nctId":"NCT00270296","phase":"PHASE2","title":"Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-06","conditions":"HIV Infections","enrollment":730},{"nctId":"NCT00086359","phase":"PHASE3","title":"Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-07","conditions":"HIV Infections","enrollment":19},{"nctId":"NCT00102206","phase":"PHASE2","title":"A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":6},{"nctId":"NCT00050895","phase":"PHASE3","title":"Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":775},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT01818258","phase":"PHASE4","title":"IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2015-10-26","conditions":"HIV Positive, Malnourished","enrollment":52},{"nctId":"NCT01352715","phase":"PHASE3","title":"Study of Options for Second-Line Effective Combination Therapy (SELECT)","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2012-03-13","conditions":"HIV-1 Infection","enrollment":515},{"nctId":"NCT03394196","phase":"NA","title":"RESIST-2: 2nd-line ART for HIV-2 Infection","status":"TERMINATED","sponsor":"University of Washington","startDate":"2018-07-04","conditions":"HIV-2 Infection","enrollment":152},{"nctId":"NCT02431975","phase":"PHASE4","title":"Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial","status":"COMPLETED","sponsor":"Columbia University","startDate":"2015-08","conditions":"HIV","enrollment":73},{"nctId":"NCT00887120","phase":"PHASE2","title":"Dose Reduction of Lopinavir in Children","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2007-04","conditions":"HIV Infections","enrollment":24},{"nctId":"NCT00621166","phase":"PHASE2","title":"Pharmacokinetics of Generic Lopinavir/Ritonavir in Pregnant Women","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2008-06","conditions":"HIV Infections","enrollment":20},{"nctId":"NCT01125696","phase":"PHASE2","title":"Safety Study of a Tenofovir-containing Drug Regimen for the Prevention of Mother-to-child Transmission of HIV and HBV","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2012-05","conditions":"HIV, Hepatitis B","enrollment":45},{"nctId":"NCT02150993","phase":"PHASE2, PHASE3","title":"First-Line Treatment for HIV-2","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2016-01-26","conditions":"HIV-2 Infection","enrollment":210},{"nctId":"NCT00993031","phase":"PHASE3","title":"Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2009-12-15","conditions":"Malaria, HIV Infections","enrollment":389},{"nctId":"NCT00978068","phase":"PHASE3","title":"HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2009-09","conditions":"Malaria, HIV Infections","enrollment":176},{"nctId":"NCT00427297","phase":"PHASE3","title":"Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya","status":"TERMINATED","sponsor":"University of Washington","startDate":"2007-09","conditions":"HIV Infections","enrollment":34},{"nctId":"NCT02231281","phase":"PHASE3","title":"Early cART and cART in Combination With Autologous HIV-1 Specific Cytotoxic T Lymphocyte (CTL) Infusion in The Treatment of Acute HIV-1 Infected Adults","status":"UNKNOWN","sponsor":"Yongtao Sun, MD, PhD","startDate":"2014-08","conditions":"Acute HIV Infection","enrollment":65},{"nctId":"NCT00949234","phase":"PHASE2","title":"Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2010-03","conditions":"HIV Prevention, HIV Infections","enrollment":267},{"nctId":"NCT01516970","phase":"PHASE3","title":"Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)","status":"COMPLETED","sponsor":"Janssen-Cilag G.m.b.H","startDate":"2011-11-25","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":312},{"nctId":"NCT00307151","phase":"PHASE2","title":"Antiviral Responses to NNRTI-Based vs. PI-Based ARV Therapy in HIV Infected Infants Who Have or Have Not Received Single Dose NVP for Prevention of Mother-to-Child Transmission of HIV","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2005-12","conditions":"HIV Infections","enrollment":452},{"nctId":"NCT00719602","phase":"EARLY_PHASE1","title":"Differences in Malaria Infection Levels in HIV-infected Infants and Children Receiving PI- and NNRTI-based HAART","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2009-08","conditions":"HIV Infections, Malaria","enrollment":105},{"nctId":"NCT00708162","phase":"PHASE3","title":"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-07","conditions":"HIV Infection","enrollment":724},{"nctId":"NCT00753324","phase":"PHASE4","title":"Routine Use of Antiretroviral Therapy to Prevent Mother-to-Child HIV Transmission in the Kafue District of Zambia","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2009-05","conditions":"HIV Infections","enrollment":284},{"nctId":"NCT01585753","phase":"","title":"MARCH Vascular Endothelium Substudy","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-06","conditions":"Cardiovascular Disease","enrollment":34},{"nctId":"NCT01637233","phase":"","title":"MARCH Central Nervous System Substudy","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-06","conditions":"HIV-1 Infection","enrollment":28},{"nctId":"NCT01637259","phase":"PHASE4","title":"MARCH Renal Substudy","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-06","conditions":"Proteinuria, HIV","enrollment":76},{"nctId":"NCT01252940","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-11","conditions":"HIV-1 Infection","enrollment":482},{"nctId":"NCT01908660","phase":"","title":"Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions","status":"COMPLETED","sponsor":"Valme University Hospital","startDate":"2007-01","conditions":"Human Immunodeficiency Virus, Hepatitis B, Chronic, Hepatitis C, Chronic","enrollment":192},{"nctId":"NCT01192035","phase":"PHASE4","title":"PI or NNRTI as First-line Treatment of HIV in West Africa - the PIONA Trial","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2011-05","conditions":"HIV-1","enrollment":400},{"nctId":"NCT01088516","phase":"PHASE4","title":"Clinical Study of an Aluvia-based HAART Regimen for Prevention of Mother-to-child HIV Transmission in Africa","status":"COMPLETED","sponsor":"University of Zambia","startDate":"2008-12","conditions":"HIV","enrollment":280},{"nctId":"NCT01583439","phase":"NA","title":"The Mochudi Prevention Project ART Protocol","status":"TERMINATED","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2012-09","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT00834457","phase":"PHASE2, PHASE3","title":"A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe","status":"COMPLETED","sponsor":"Parirenyatwa Hospital","startDate":"2007-06","conditions":"AIDS-related Kaposi's Sarcoma","enrollment":49},{"nctId":"NCT00143689","phase":"PHASE4","title":"NRTI-Sparing Pilot Study","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2002-04","conditions":"HIV, Mitochondrial Toxicity","enrollment":13},{"nctId":"NCT00624195","phase":"PHASE2, PHASE3","title":"Clinical Trial of CNS-targeted HAART (CIT2)","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2007-03","conditions":"HIV Infections","enrollment":59},{"nctId":"NCT00234091","phase":"PHASE3","title":"When to Start Anti-HIV Drugs in Children Infected With HIV (The PREDICT Study)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-04","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00865475","phase":"PHASE4","title":"Prevention of Lipoatrophy in Patients Treated With Lopinavir/Ritonavir in Monotherapy Versus ZDV + 3TC + ABC","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2008-12","conditions":"HIV Infection, HIV Infections","enrollment":38},{"nctId":"NCT01772940","phase":"PHASE4","title":"Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Saint Pierre","startDate":"2008-12","conditions":"HIV-1 Infection","enrollment":425},{"nctId":"NCT00050908","phase":"","title":"Blood Vessel Function in HIV-Infected Patients Taking Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":75},{"nctId":"NCT00014937","phase":"NA","title":"Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":240},{"nctId":"NCT00424814","phase":"PHASE2, PHASE3","title":"Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. ANRS 135 Primeva","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2007-03","conditions":"HIV Infections","enrollment":105},{"nctId":"NCT00342355","phase":"PHASE4","title":"Antiretroviral Therapy for Advanced HIV Disease in South Africa","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2004-01","conditions":"HIV","enrollment":1771},{"nctId":"NCT00666055","phase":"","title":"Sex, Aging and Antiretroviral Pharmacokinetics","status":"COMPLETED","sponsor":"Kristine Patterson, MD","startDate":"2008-03","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT00034086","phase":"NA","title":"Study of Anti-HIV Therapy Intensification","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":22},{"nctId":"NCT00192621","phase":"PHASE4","title":"Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2004-11","conditions":"HIV Infections, Dyslipidemias, Glucose Metabolism Disorders","enrollment":50},{"nctId":"NCT00936195","phase":"PHASE3","title":"Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women : a Phase 3 Trial","status":"WITHDRAWN","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2010-01","conditions":"HIV Infection, Pregnancy, Breastfeeding","enrollment":""},{"nctId":"NCT00405925","phase":"PHASE3","title":"FREE Study: Efficacy and Toxicity of Trizivir","status":"COMPLETED","sponsor":"Rijnstate Hospital","startDate":"2003-03","conditions":"HIV Infections","enrollment":207},{"nctId":"NCT00164736","phase":"PHASE3","title":"Breastfeeding, Antiretroviral, and Nutrition Study","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2004-03","conditions":"HIV Infections","enrollment":2369},{"nctId":"NCT00385645","phase":"PHASE4","title":"Atazanavir or Lopinavir in HIV Post-exposure Prophylaxis","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2006-05","conditions":"HIV Infections","enrollment":255},{"nctId":"NCT00966160","phase":"PHASE3","title":"CD4 Cell Recovery in HIV-1 Patients Comparing 2 Treatment Regimes","status":"COMPLETED","sponsor":"University of Cologne","startDate":"1999-01","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":215},{"nctId":"NCT00234923","phase":"PHASE3","title":"Efficacy and Safety of Kaletra Monotheraphy Compared to Kaletra Based Triple Therapy to Treat HIV in Antiretroviral Naїve Patients","status":"COMPLETED","sponsor":"Abbott","startDate":"2003-08","conditions":"HIV Infection","enrollment":138},{"nctId":"NCT00043953","phase":"PHASE2","title":"Lopinavir/Ritonavir in Combination With Saquinavir Mesylate or Lamivudine/Zidovudine to Explore Metabolic Toxicities in Antiretroviral HIV-Infected Subjects","status":"COMPLETED","sponsor":"Abbott","startDate":"2002-08","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT00080522","phase":"NA","title":"Strategies for Delivering Anti-HIV Therapy in South Africa","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-02","conditions":"HIV Infections","enrollment":813},{"nctId":"NCT00075231","phase":"PHASE2","title":"A Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects","status":"COMPLETED","sponsor":"Abbott","startDate":"2003-12","conditions":"HIV Infections","enrollment":150},{"nctId":"NCT00162643","phase":"PHASE4","title":"PI Vs. NNRTI Based Therapy for HIV Advanced Disease","status":"UNKNOWN","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2004-12","conditions":"Acquired Immunodeficiency Syndrome","enrollment":300},{"nctId":"NCT00122226","phase":"PHASE4","title":"MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)","status":"UNKNOWN","sponsor":"Amsterdam UMC, location VUmc","startDate":"2003-01","conditions":"HIV Infections, HIV-Associated Lipodystrophy Syndrome","enrollment":50},{"nctId":"NCT00139178","phase":"PHASE4","title":"Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir.","status":"COMPLETED","sponsor":"Danish HIV Research Group","startDate":"2004-03","conditions":"HIV Associated Lipodystrophy Syndrome., HIV, Hypercholesterolemia","enrollment":100}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ABORTION SPONTANEOUS"},{"count":1,"reaction":"MATERNAL EXPOSURE DURING PREGNANCY"}],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"zidovudine+lamivudine+lopinavir/ritonavir","genericName":"zidovudine+lamivudine+lopinavir/ritonavir","companyName":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","companyId":"instituto-nacional-de-ciencias-medicas-y-nutricion-salvador-zubiran","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination inhibits HIV replication by blocking reverse transcriptase (zidovudine and lamivudine) and protease (lopinavir/ritonavir) enzymes required for viral reproduction. Used for HIV-1 infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}